{
    "Trade/Device Name(s)": [
        "EliA SmDP Immunoassay"
    ],
    "Submitter Information": "Phadia US, Inc.",
    "510(k) Number": "K132631",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LKP"
    ],
    "Summary Letter Date": "July 28, 2014",
    "Summary Letter Received Date": "July 31, 2014",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR866.5100"
    ],
    "Regulation Name(s)": [
        "Antinuclear Antibody Immunological Test System"
    ],
    "Analyte Class(es)": [
        "autoimmune",
        "immunology"
    ],
    "Analyte(s)": [
        "IgG antibodies to Sm"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "EDTA tube",
        "Citrate tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Phadia 100",
        "Phadia 250"
    ],
    "Method(s)/Technology(ies)": [
        "EliA IgG immunoassay"
    ],
    "Methodologies": [
        "Immunoassay",
        "Semi-quantitative measurement"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for EliA SmDP Immunoassay for semi-quantitative detection of IgG antibodies to Sm in serum and plasma using EliA IgG method on Phadia 100/250 instruments",
    "Indications for Use Summary": "Intended for the in vitro semi-quantitative measurement of IgG antibodies directed to Sm in human serum and plasma (EDTA, citrate) as an aid in the clinical diagnosis of systemic lupus erythematosus (SLE) in conjunction with other laboratory and clinical findings",
    "fda_folder": "Immunology"
}